Dr. Jamie E. Chaft, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 262
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Medical school: New York University School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 247218 -
Internal Medicine Physician
NY license 247218
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Msk Monmouth (295 clinicians)
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 262
- Services billed
- 1,034
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 446 | 222 |
| Established patient office or other outpatient visit, 40-54 minutes | 389 | 190 |
| Established patient office or other outpatient visit, 20-29 minutes | 214 | 105 |
| New patient office or other outpatient visit, 60-74 minutes | 73 | 73 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 40 | 17 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 30 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 298 |
| Dexamethasone Other prescribers in New York, NY | 109 |
| Prochlorperazine Maleate Other prescribers in New York, NY | 68 |
| Prednisone Other prescribers in New York, NY | 57 |
| Levothyroxine Sodium Other prescribers in New York, NY | 53 |
| Pantoprazole Sodium Other prescribers in New York, NY | 40 |
| Lorbrena (lorlatinib) | 37 |
| Xarelto (rivaroxaban) Other prescribers in New York, NY | 36 |
| Folic Acid Other prescribers in New York, NY | 35 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New York, NY | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 26 payments worth $38,929 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $14,345 |
|---|---|
| Eli Lilly and Company | $9,900 |
| AstraZeneca UK Limited | $5,375 |
| EMD Serono, Inc. | $3,800 |
| Merck Sharp & Dohme LLC | $3,090 |
| Nuvation Bio Inc. | $2,100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $169 |
| Genentech USA, Inc. | $151 |
| Consulting Fee | $34,660 |
|---|---|
| Travel and Lodging | $3,297 |
| Food and Beverage | $973 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Jan 6, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $9,900 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee IMFINZI · Oncology | $4,920 |
| AstraZeneca Pharmaceuticals LP Jun 9, 2025 | Consulting Fee IMFINZI · Oncology | $4,920 |
| AstraZeneca Pharmaceuticals LP Nov 20, 2025 | Consulting Fee TAGRISSO · Oncology | $4,100 |
| EMD Serono, Inc. Dec 23, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,800 |
| AstraZeneca UK Limited May 12, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $3,280 |
| Nuvation Bio Inc. Dec 29, 2025 | Consulting Fee IBTROZI · Oncology | $2,100 |
| AstraZeneca UK Limited Jul 9, 2025 | Consulting Fee TAGRISSO · Oncology Company’s descriptionResearch Related Service | $1,640 |
| Merck Sharp & Dohme LLC Jan 14, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $1,640 |
| AstraZeneca UK Limited Jun 2, 2025 | Travel and Lodging travel to Chicago, IL · in-kind Company’s descriptionResearch Related Service | $417 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Nuvation Bio Inc. Dec 29, 2025 | Consulting Fee IBTROZI · Oncology | $2,100 |
| EMD Serono, Inc. Dec 23, 2025 | Consulting FeeCompany’s descriptionAdvisory Board Participation (Fee For Service) | $3,800 |
| AstraZeneca Pharmaceuticals LP Nov 20, 2025 | Consulting Fee TAGRISSO · Oncology | $4,100 |
| AstraZeneca Pharmaceuticals LP Nov 6, 2025 | Consulting Fee IMFINZI · Oncology | $4,920 |
| AstraZeneca UK Limited Jul 9, 2025 | Consulting Fee TAGRISSO · Oncology Company’s descriptionResearch Related Service | $1,640 |
| AstraZeneca Pharmaceuticals LP Jun 9, 2025 | Consulting Fee IMFINZI · Oncology | $4,920 |
| AstraZeneca UK Limited Jun 2, 2025 | Travel and Lodging travel to Chicago, IL · in-kind Company’s descriptionResearch Related Service | $417 |
| AstraZeneca UK Limited May 12, 2025 | Consulting Fee IMFINZI · Oncology Company’s descriptionResearch Related Service | $3,280 |
| Merck Sharp & Dohme LLC Feb 6, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA Company’s descriptionProvided as part of a clinical research engagement. | $214 |
| Merck Sharp & Dohme LLC Jan 16, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $154 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $326 |
| Merck Sharp & Dohme LLC Jan 15, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $221 |
| Merck Sharp & Dohme LLC Jan 14, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $1,640 |
| Merck Sharp & Dohme LLC Jan 14, 2025 | Travel and Lodging VACCINE · travel to La Jolla, CA · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $326 |
| Eli Lilly and Company Jan 6, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $9,900 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $6,453,551 in research payments for these studies, mostly to the institutions running them.
- A randomized Phase 3 study of nivolumab after surgical resection and adjuvant chemotherapy in Non Small Cell Lung Cancer
E.r. Squibb & Sons, L.l.c. - An open-label, randomized, multicenter, Phase 3 study to assess the efficacy and safety of Trastuzumab Deruxtecan as first-line treatment of unresectable, locally advanced or metastatic NSCLC harboring a HER2 exon 19 …
AstraZeneca Pharmaceuticals LP - A phase II study of induction AMG 510 mono- and combination therapy for surgically resectable stage IB-IIIB non-squamous NSCLC bearing a KRASG12C-mutation
Amgen Inc. - NAUTIKA1 previously LCMC4
Genentech, Inc. - A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
Beigene, Ltd. · Completed · NCT05635708 - A phase 3, multicenter, double-blind, placebo-controlled study assessing the efficacy and safety of olomorasib in combination with standard of care immunotherapy in participants with resected or unresectable kras G12C…
Eli Lilly and Company - A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SoC Chemotherapy Alone for the Treatment of Patients with Epidermal Growth F…
AstraZeneca Pharmaceuticals LP - A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
AstraZeneca Pharmaceuticals LP - A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adjuvant Therapy for Participants with Resectable Stage II, IIIA, and Resectable IIIB T3-4N2 Non-sma…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.